Alpha Tau Medical Ltd. DRTS
12.09 USD +0.12 (+1.00%)
Regular-session close
12.25 +0.16 +1.32%
After hours · Nov 17, 7:38 PM ET
11.67 Day range 12.30
3.43 52-week range 15.79
- YTD
- +144.24%
- 1 year
- +217.32%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
seekingalpha.com Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
benzinga.com Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients Alpha Tau Medical Ltd. (NASDAQ:DRTS) on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.
benzinga.com Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients Alpha Tau Medical reports a 100% objective response rate and strong safety in interim U.S. REGAIN glioblastoma trial data.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS)…
benzinga.com Why Take-Two Interactive Software Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.benzinga.com Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment…
globenewswire.com Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16 - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment…
globenewswire.com Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial JERUSALEM, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today…
benzinga.com This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded RSG, AAPL, MRCY, DK and DRTS, revising price targets, including AAPL to $425 and DRTS to $22.benzinga.com Piper Sandler Upgrades Alpha Tau Medical to Overweight, Raises Price Target to $22 Piper Sandler analyst Allison Bratzel upgrades Alpha Tau Medical (NASDAQ:DRTS) from Neutral to Overweight and raises the price target from $8 to $22.
benzinga.com Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdingsTA-125 tracks the 125 largest and most prominent companies on the TASEJERUSALEM, Oct. 29, 2026…
globenewswire.com Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026…benzinga.com Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea,…
globenewswire.com Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea - MOU relates to a potential clinical trial in South Korea, Alpha DaRT's first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea,…benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
benzinga.com Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration…
globenewswire.com Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting - FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua…
globenewswire.com Alpha Tau to Participate in October Investor Conferences JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,…
seekingalpha.com Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's…
seekingalpha.com Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients…
globenewswire.com Alpha Tau to Participate in September Investor Conferences JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
globenewswire.com Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions - IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12…
defenseworld.net PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two…
globenewswire.com Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,…
globenewswire.com Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with…
defenseworld.net Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) shares rose 7.1% on Friday. The company traded as high as $12.53 and last traded at $12.7280. 196,591 shares were traded during trading, a…
globenewswire.com Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
zacks.com New Strong Sell Stocks for July 7th AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
zacks.com New Strong Sell Stocks for July 2nd DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
gurufocus.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
